TRIUMVIRA IMMUNOLOGICS
Triumvira Immunologics, Inc. (“Triumvira”) is an immunotherapy company co-founded in 2015 by Dr. Jonathan Bramson at McMaster University and Bloom Burton & Co., with the vision of developing novel T cell therapies that are safer and more efficacious than current cancer treatments, including chimeric antigen receptor (CAR) and engineered T cell receptor (TCR) therapies. Their proprietary T cell Antigen Coupler (TAC) technology recruits the entire natural T cell receptor and is independent of the major histocompatibility complex (MHC), allowing for the development of better therapies for a broader range of patients with solid or liquid malignancies and also with diseases other than cancer.
TRIUMVIRA IMMUNOLOGICS
Industry:
Biotechnology Clinical Trials Health Care
Founded:
2015-01-01
Address:
Austin, Texas, United States
Country:
United States
Website Url:
http://www.triumvira.com
Total Employee:
51+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
100 M USD
Technology used in webpage:
SPF Person Schema Microsoft Exchange Online Google Office 365 Mail Google Cloud GoDaddy DNS Google Cloud Oregon
Similar Organizations
Century Therapeutics
Century Therapeutics is a developer of allogeneic living drugs created to offer treatment for cancer.
Eureka Therapeutics
Eureka Therapeutics is a biotechnology company focusing on immunotherapies for the treatment of cancer.
Gritstone Bio
Gritstone Oncology is a clinical-stage biotech company that develops tumor-specific cancer immunotherapies to fight multiple cancer types.
Navrogen
Navrogen is a biopharmaceutical company focused on the targeted treatment of cancer.
Tmunity Therapeutics
Tmunity Therapeutics is developing novel products to unleash the immunological potential of T cells
Vittoria Biotherapeutics
Vittoria Biotherapeutics is a gene-edited cell therapeutics company.
Current Advisors List
Current Employees Featured
Founder
Investors List
Myeloma Investment Fund
Myeloma Investment Fund investment in Series A - Triumvira Immunologics
Multiple Myeloma Research Foundation
Multiple Myeloma Research Foundation investment in Series A - Triumvira Immunologics
Northpond Ventures
Northpond Ventures investment in Series A - Triumvira Immunologics
Leaps by Bayer
Leaps by Bayer investment in Series A - Triumvira Immunologics
B Capital
B Capital investment in Series A - Triumvira Immunologics
ATEM Capital Fund LP
ATEM Capital Fund LP investment in Series A - Triumvira Immunologics
Northpond Ventures
Northpond Ventures investment in Series A - Triumvira Immunologics
Bloom Burton & Co.
Bloom Burton & Co. investment in Series A - Triumvira Immunologics
Centre for Commercialization of Cancer Immunotherapy
Centre for Commercialization of Cancer Immunotherapy investment in Series A - Triumvira Immunologics
Leaps by Bayer
Leaps by Bayer investment in Series A - Triumvira Immunologics
Key Employee Changes
Official Site Inspections
http://www.triumvira.com Semrush global rank: 5 M Semrush visits lastest month: 1.66 K
- Host name: 47.107.198.104.bc.googleusercontent.com
- IP address: 104.198.107.47
- Location: Mountain View United States
- Latitude: 37.4043
- Longitude: -122.0748
- Metro Code: 807
- Timezone: America/Los_Angeles
- Postal: 94043
More informations about "Triumvira Immunologics"
Company Overview - Triumvira Immunologics | Car-T, …
Triumvira is developing unique, targeted autologous and allogeneic T cell therapeutics that co-opt the natural biology of T cells to treat a broad range of patients with cancer. Our company is backed by a strong intellectual property …See details»
Triumvira Immunologics - Crunchbase Company Profile & Funding
Triumvira Immunologics, Inc. (“Triumvira”) is an immunotherapy company co-founded in 2015 by Dr. Jonathan Bramson at McMaster University and Bloom Burton & Co., with the vision of …See details»
Triumvira Immunologics, Inc.
Nov 1, 2024 Explore Triumvira Immunologics, Inc. with its drug pipeline, therapeutic area, technology platform, 3 clinical trials, 56 news, and 10 literature, Disease Domain:Neoplasms, …See details»
About Us - Triumvira Immunologics | Car-T, TCR, TAC Therapies …
©2024 Triumvira Immunologics. About Us; Leadership; Pipeline; TAC101-CLDN18.2; Careers; Contact; Privacy Policy; Terms & ConditionsSee details»
Triumvira Company Profile 2024: Valuation, Funding
Triumvira General Information Description. Developer of immunotherapy-based drugs designed to provide novel T-cell therapies for cancer treatment. The company's technology recruits the entire natural T-cell receptor and functions …See details»
Triumvira Immunologics - The Org
At Triumvira Immunologics, Inc., our team is dedicated to a vision of finding a cure and providing new hope for patients with life-threatening disease. Co-founded in 2015 by licensing …See details»
Triumvira Company Profile - Office Locations, Competitors ... - Craft
Triumvira Immunologics is an immunotherapy company. Its T cell Antigen Coupler (TAC) technology recruits the entire natural T cell receptor and is independent of the major …See details»
Triumvira Immunologics - Overview, News & Similar companies
Jul 20, 2023 Who is Triumvira Immunologics. Triumvira Immunologics, Inc. ("Triumvira") is a clinical stage immunotherapy company with the vision of developing novel T cell therapies that …See details»
Triumvira Immunologics - Funding, Financials, Valuation & Investors
Triumvira Immunologics is an immunotherapy company that develops novel T cell therapies for cancer. Search Crunchbase. Start Free Trial . Chrome Extension. Solutions. ... How much …See details»
Triumvira Immunologics (USA) Funding: $100M
Nov 26, 2024 Triumvira Immunologics is an immunotherapy company with the vision of developing novel T cell therapies that are safer and more efficacious than current cancer …See details»
First in class engineered T cells for safer, more ... - Triumvira
Triumvira’s current focus is on gastric cancer The continued reliance on chemo-based regimens in second and third-line settings create a near-term opportunity to help patients with few options …See details»
Triumvira Immunologics' Late-Breaking Abstract Selected for Oral ...
Nov 11, 2024 Triumvira Immunologics, a clinical-stage company developing novel, targeted autologous and allogeneic T cell therapeutics that co-opt the natural biology of T cells to treat …See details»
Triumvira is Creating a Different Picture for Cancer Patients
Sep 22, 2021 Triumvira President and CEO Dr. Paul Lammers/Courtesy Triumvira Immunologics. Triumvira Immunologics has an alternative to chimeric antigen receptor (CAR) …See details»
First in class engineered T cells for safer, more efficacious and ...
Triumvira is building a foundation in gastric & gastro-intestinal cancer Expansion into other tumors and therapeutic areas through existing pipeline and partnerships Platform Target Indication …See details»
Triumvira Immunologics' Late-Breaking Abstract Selected for Oral ...
Nov 11, 2024 Triumvira Immunologics, Inc. ("Triumvira") is a leading clinical-stage solid tumor cell therapy company developing unique, non-gene edited, first-in-class targeted autologous …See details»
Triumvira Immunologics, Inc. (Triumvira Immunologics, Inc.) - 药物 …
了解Triumvira Immunologics, Inc. (Triumvira Immunologics, Inc.)公司的药物管线，治疗领域，技术平台，以及它的3项临床试验, 68篇新闻和10篇文献，疾病领域:肿瘤，内分泌与代谢疾病， …See details»
Triumvira Expands Management Team with Chief Medical Officer …
May 17, 2018 Triumvira Immunologics, Inc. (“Triumvira”) is an immunotherapy company co-founded in 2015 by Dr. Jonathan Bramson at McMaster University and Bloom Burton & Co., …See details»
What is Triumvira? Company Culture, Mission, Values
Glassdoor gives you an inside look at what it's like to work at Triumvira, including salaries, reviews, office photos and more. This is the Triumvira company profile. All content is posted …See details»
Careers - Triumvira Immunologics | Car-T, TCR, TAC Therapies and ...
Our Culture . We are dedicated to fostering a collegial, fast-paced, and low ego environment that leads to productive collaboration. Putting patients at the heart of our work, we consistently …See details»